Literature DB >> 8678441

Surgical implications of tumour immunology.

S S Somers1.   

Abstract

The presence of immune infiltration of tumour deposits and the existence of effective in vitro anti-tumour immune responses would suggest the possibility of therapeutic manipulation against tumour cells. However, clinical immunotherapy has shown little promise as a cancer treatment. Numerous explanations for this inefficacy have been proposed, one of which involves the elaboration of immunosuppressive moieties from tumour cells. The results of studies presented below show that serum from patients with gastrointestinal and other tumours have immunosuppressive influences on normal lymphocytes. The degree of this in vitro inhibition is related to tumour 'bulk' and may reflect a systemic immunosuppressive influence of the tumour. Isolation and culture of lymphocytes from gastrointestinal tumour deposits demonstrated that these immune cells are functionally inert, suggesting the existence of an immunosuppressive tumour microenvironment. The isolation and partial purification of an immunosuppressive moiety from conditioned culture medium of a variety of human tumour cell lines further supports the hypothesis of tumour-mediated immunosuppression. A number of protein tumour cell products have been described with potent immunosuppressive properties. These include transforming growth factor-beta, interleukin-10, and the retroviral envelope protein p15E. The surgical implications of the proposed tumour-host immune relationship includes the hypothesis that clinically apparent disease may not be amenable to immune attack owing to tumour-mediated immune suppression. The use of immunostimulatory strategies as adjuvant perioperative therapy would seem a more effective environment for the activation of antitumour immune responses in the surgical patient.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8678441      PMCID: PMC2502549     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  18 in total

1.  Macrophage infiltration of breast tumours: a prospective study.

Authors:  I Lauder; W Aherne; J Stewart; R Sainsbury
Journal:  J Clin Pathol       Date:  1977-06       Impact factor: 3.411

2.  Impaired immunologic reactivity and recurrence following cancer surgery.

Authors:  F R Eilber; D L Morton
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

3.  Generation of activated killer cells in tumor-bearing hosts.

Authors:  C C Ting; M E Hargrove; D Stephany
Journal:  Int J Cancer       Date:  1987-02-15       Impact factor: 7.396

4.  Characterization of an immunosuppressive factor derived from colon cancer cells.

Authors:  E C Ebert; A I Roberts; S M O'Connell; F M Robertson; H Nagase
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

5.  Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.

Authors:  E Gorelik; R H Wiltrout; K Okumura; S Habu; R B Herberman
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

6.  In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas.

Authors:  S T Yuen; L P Chung; S Y Leung; I S Luk; S Y Chan; J Ho
Journal:  Am J Surg Pathol       Date:  1994-11       Impact factor: 6.394

7.  Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer.

Authors:  J R Monson; C W Ramsden; G R Giles; T G Brennan; P J Guillou
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

8.  Suppressor cell activity in melanoma patients. I. Relation to tumor growth an immunoglobulin levels in vivo.

Authors:  J Werkmeister; W McCarthy; P Hersey
Journal:  Int J Cancer       Date:  1981-07-15       Impact factor: 7.396

9.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.